{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:37:54Z","timestamp":1783399074779,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10157-024-02508-4","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T01:02:35Z","timestamp":1717462955000},"page":"1082-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"28","author":[{"given":"Eiichiro","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-6514","authenticated-orcid":false,"given":"Izaya","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"2508_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753\u201379. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015.","journal-title":"Kidney Int"},{"key":"2508_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2215\/cjn.07180622","volume":"17","author":"RE Campbell","year":"2022","unstructured":"Campbell RE, Thurman JM. The immune system and idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2022;17:1823\u201334. https:\/\/doi.org\/10.2215\/cjn.07180622.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2508_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","volume":"39","author":"M Nakayama","year":"2002","unstructured":"Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39:503\u201312. https:\/\/doi.org\/10.1053\/ajkd.2002.31400.","journal-title":"Am J Kidney Dis"},{"key":"2508_CR4","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635\u201342. https:\/\/doi.org\/10.1182\/blood-2004-03-1110.","journal-title":"Blood"},{"key":"2508_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(14)60541-9.","journal-title":"Lancet"},{"key":"2508_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000300","volume":"93","author":"Y Iwabuchi","year":"2014","unstructured":"Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore). 2014;93: e300. https:\/\/doi.org\/10.1097\/md.0000000000000300.","journal-title":"Medicine (Baltimore)"},{"key":"2508_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","volume":"14","author":"C Xue","year":"2021","unstructured":"Xue C, Yang B, Xu J, Zhou C, Zhang L, Gao X, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J. 2021;14:1042\u201354. https:\/\/doi.org\/10.1093\/ckj\/sfaa191.","journal-title":"Clin Kidney J"},{"key":"2508_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000533695","volume":"3","author":"A Aslam","year":"2023","unstructured":"Aslam A, Koirala A. Review of the role of rituximab in the management of adult minimal change disease and immune-mediated focal and segmental glomerulosclerosis. Glomerular Dis. 2023;3:211\u20139. https:\/\/doi.org\/10.1159\/000533695.","journal-title":"Glomerular Dis"},{"key":"2508_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s10157-021-02098-5","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S, et al. A digest of the evidence-based clinical practice guideline for nephrotic syndrome 2020. Clin Exp Nephrol. 2021;25:1277\u201385. https:\/\/doi.org\/10.1007\/s10157-021-02098-5.","journal-title":"Clin Exp Nephrol"},{"key":"2508_CR10","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","volume":"29","author":"J Guitard","year":"2014","unstructured":"Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29:2084\u201391. https:\/\/doi.org\/10.1093\/ndt\/gfu209.","journal-title":"Nephrol Dial Transplant"},{"key":"2508_CR11","doi-asserted-by":"publisher","first-page":"28799","DOI":"10.18632\/oncotarget.25612","volume":"9","author":"R Fenoglio","year":"2018","unstructured":"Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018;9:28799\u2013804. https:\/\/doi.org\/10.18632\/oncotarget.25612.","journal-title":"Oncotarget"},{"key":"2508_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28:1225\u201332. https:\/\/doi.org\/10.1093\/ndt\/gfs515.","journal-title":"Nephrol Dial Transplant"},{"key":"2508_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5414\/cn110245","volume":"95","author":"K Fujimoto","year":"2021","unstructured":"Fujimoto K, Kagaya Y, Kumano S, Fujii A, Tsuruyama Y, Matsuura T, et al. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab. Clin Nephrol. 2021;95:29\u201336. https:\/\/doi.org\/10.5414\/cn110245.","journal-title":"Clin Nephrol"},{"key":"2508_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ndt\/gft312","volume":"29","author":"A Bruchfeld","year":"2014","unstructured":"Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2014;29:851\u20136. https:\/\/doi.org\/10.1093\/ndt\/gft312.","journal-title":"Nephrol Dial Transplant"},{"key":"2508_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000477944","volume":"46","author":"D Roccatello","year":"2017","unstructured":"Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, et al. High-dose rituximab ineffective for focal segmental glomerulosclerosis: a long-term observation study. Am J Nephrol. 2017;46:108\u201313. https:\/\/doi.org\/10.1159\/000477944.","journal-title":"Am J Nephrol"},{"key":"2508_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol. 2022;37:1057\u201366. https:\/\/doi.org\/10.1007\/s00467-021-05304-4.","journal-title":"Pediatr Nephrol"},{"key":"2508_CR17","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","volume":"38","author":"A Zurowska","year":"2023","unstructured":"Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M, et al. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol. 2023;38:3035\u201342. https:\/\/doi.org\/10.1007\/s00467-023-05913-1.","journal-title":"Pediatr Nephrol"},{"key":"2508_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138. https:\/\/doi.org\/10.1007\/s00467-009-1191-0.","journal-title":"Pediatr Nephrol"},{"key":"2508_CR19","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/asn.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pell\u00e9 T, Gaspari F, et al. Anti-phospholipase a2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26:2545\u201358. https:\/\/doi.org\/10.1681\/asn.2014070640.","journal-title":"J Am Soc Nephrol"},{"key":"2508_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/asn.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33:238\u201342. https:\/\/doi.org\/10.1681\/asn.2021060794.","journal-title":"J Am Soc Nephrol"},{"key":"2508_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","volume":"89","author":"A Jamin","year":"2018","unstructured":"Jamin A, Berthelot L, Couderc A, Chemouny JM, Boedec E, Dehoux L, et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. J Autoimmun. 2018;89:149\u201361. https:\/\/doi.org\/10.1016\/j.jaut.2017.12.014.","journal-title":"J Autoimmun"},{"key":"2508_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncprheum0983","volume":"5","author":"SK Datta","year":"2009","unstructured":"Datta SK. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol. 2009;5:80\u20132. https:\/\/doi.org\/10.1038\/ncprheum0983.","journal-title":"Nat Clin Pract Rheumatol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02508-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T13:09:00Z","timestamp":1731676140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02508-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2508"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02508-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Iwate Prefectural Central Hospital and conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was not obtained from the patients because the ethical guidelines for epidemiological research in Japan do not require informed consent for a retrospective cohort study using only existing medical records.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}